UCB extends label for Cimzia to cover rare autoimmune condition

Belgium’s UCB (Euronext: UCB) has won an expansion to the label for Cimzia (certolizumab pegol) in the USA, to include certain adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

The approval makes Cimzia the first and only US FDA-approved treatment for nr-axSpA, a chronic inflammatory condition which mainly affects the spine and sacroiliac joints.

Immunology head Emmanuel Caeymaex said: “The FDA approval of Cimzia for adults with non-radiographic axial spondyloarthritis will be transformative for the many patients living with this disease.”